drugset / Trial / NCT00038103

Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen

NCT00038103

Phase 2 Completed 111 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, randomized (1:1 randomization ratio) study of either exemestane or exemestane plus celecoxib in postmenopausal women with ABC having progressed on tamoxifen.

Timeline

Start
2002-01
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 400 mg Oral
Comparator Exemestane Small molecule 25 mg Oral

Indications